II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of avapro more for patients It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including avapro more for patients Karvezide.

a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive avapro more for patients effect. Irbesartan/hydrochlorothiazide avapro more for patients preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker avapro more for patients Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due avapro more for patients type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: avapro more for patients Medicines avapro more for patients 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 IrbesartanFrom Wikipedia, the free encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic avapro more for patients name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number.

Clinical useMain article: avapro more for patients II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was.